Drug intelligence / Profile preview

Qiangxin Fumai Granules

Development stage: Phase 1
Lead developer: Jilin Connell Pharmaceutical
Administration: Oral

Overview

Qiangxin Fumai Granules is a Traditional Chinese Medicine (TCM) product developed by Jilin Cornell Pharmaceutical Co., Ltd. for the treatment of cardiovascular conditions, specifically arrhythmias such as bradyrhythmia and associated symptoms like palpitations. It is formulated as granules for oral administration. Clinical development has reached Phase 1 trials in China, focusing on safety, tolerability, and pharmacokinetics in healthy subjects to determine appropriate dosing for subsequent Phase 2 studies.

Brand names: Qiangxin Fumai Granules
Other names: Qiangxin Fumai Keli强心复脉颗粒

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CTNNB1 (Beta-catenin)TP53 (Cellular Tumor Antigen p53 R175H)ADRB1 (β1)HCN4 (Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4)

Beyond the preview

Go deeper on Qiangxin Fumai Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qiangxin Fumai Granules.